Advertisement
Home Tags Diabetes: Type II

Tag: Diabetes: Type II

Fenofibrate therapy may reduce cardiovascular disease in statin-treated patients with diabetes and dyslipidemia

Fenofibrate May Reduce CVD in Patients With DM, Dyslipidemia

No reduction in primary outcome for 4,644 ACCORD participants followed for median of 9.7 years
For patients with chronic kidney disease

Metformin Tied to Better Clinical Outcomes in CKD, CHF, CLD

Reduced all-cause death for chronic kidney disease, congestive heart failure, chronic liver disease
The American College of Physicians has updated recommendations on the oral pharmacologic treatment of type 2 diabetes in adults. The clinical practice guideline update was published online Jan. 3 in the Annals of Internal Medicine.

ACP Updates Recommendations for Oral Medications in T2DM

Recs serve as update to 2012 American College of Physicians guideline
For patients with type 2 diabetes on insulin therapy

Lactobacillus Supplement Doesn’t Impact HbA1c in Type 2 Diabetes

Patients receiving highest dose of L. reuteri have increases in insulin sensitivity index versus baseline
For patients with type 2 diabetes

Luseogliflozin Effective for T2DM With Low-Carb, High-Carb Diet

Similar efficacy when meals contain 40 to 55 percent total energy from carbohydrate
For patients with type 2 diabetes

Postprandial Hyperglycemia Linked to CVD Incidence in T2DM

Association with cardiovascular disease and mortality is independent of mean HbA1c level
Whites with type 2 diabetes have more life years lost than South Asians or blacks

More Years Lost for Whites Versus South Asians, Blacks With T2DM

Older South Asians with diabetes have longer life expectancy than South Asians without diabetes
Patients with type 2 diabetes have higher prevalence of chronic hepatitis B virus infection

Chronic Hepatitis B Prevalence Higher in Those With T2DM

Findings based on comparison to adult-onset autoimmune diabetes, controls
For patients with type 2 diabetes

Lowest Glucose Variability for Insulin + GLP-1 RA in T2DM

Lowest glucose variability, hypoglycemia for basal insulin + GLP-1 receptor agonist regimen
For patients with type 2 diabetes mellitus

Long-Term DPP4-Inhibitor Use Not Tied to Fracture Risk in T2DM

No increase in risk of any fracture, osteoporotic or hip fractures with continuous long-term use